FDA approves Protein Sciences' flu vaccine Flublok

01/16/2013 | HealthDay News

Protein Sciences received FDA approval for its new flu vaccine, Flublok, for patients aged 18 to 49. The vaccine "offers the potential for faster startup of the vaccine manufacturing process in the event of a pandemic, because it is not dependent on an egg supply or on availability of the influenza virus," an agency official said. The production method uses recombinant DNA and insect virus expression technology, which have been used in other vaccines.

View Full Article in:

HealthDay News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA